Compositions and methods for treating infections
The invention relates to inhibitors of dihydrofolate reductase and pharmaceutical preparations thereof. The invention further relates to methods of treatment of parasitic infections, such as T. gondii, T. cruzi, P. falciparum, T. brucei , or L. major infections, using the novel inhibitors of the invention.
1. A method of treating a protozoan infection, comprising administering to a patient in need thereof a compound having the structure of formula (I), a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or salt:
wherein:
R 1 is H, C 1-6 alkyl, C 3-6 cycloalkyl, C 4-8 cycloalkylalkyl, or halogen;
W is N or CR 18 and Z is N or CR 17 , provided that at least one of W and Z is N;
R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 17 , and R 18 are independently selected from H, C 1-6 alkyl, C 3-6 cycloalkyl, hydroxyl and fluorine; provided that at least four of R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 are H; if W is N, then none of R 2 , R 3 , R 6 , and R 7 is hydroxyl; and if Z is N, then none of R 4 , R 5 , R 8 , and R 9 is hydroxyl; and
R 10 is substituted or unsubstituted C 6-10 aryl or 5- to 10-membered heteroaryl,
wherein the infection is caused by an Apicomplexan protozoan, wherein the genus of the protozoan is selected from Toxoplasma, Leishmania , and Trypanosoma.
2. The method of claim 1 , wherein the genus of the protozoan is Toxoplasma.
3. The method of claim 1 , wherein the protozoan is selected from T. gondii, T. cruzi, T. brucei, and L. major.
4. The method of claim 3 , wherein the protozoan is selected from T. gondii, T. cruzi , and T. brucei.
5. The method of claim 1 , wherein R 10 is phenyl substituted with R 12 and R 12 is selected from C 6 aryl, 5- or 6-membered heteroaryl, and 4 to 7-membered heterocyclyl.
6. The method of claim 1 , wherein the compound has the structure of formula (Ia):
7. The method of claim 6 , wherein R 10 is C 6 aryl.
8. The method of claim 7 , wherein R 10 is phenyl substituted with R 12 and R 12 is selected from C 6 aryl, 5- or 6-membered heteroaryl, and 4 to 7-membered heterocyclyl.
9. The method of claim 8 , wherein the infection is toxoplasmosis.
10. The method of claim 8 , wherein R 10 is phenyl substituted with R 12 at the meta position.
11. The method of claim 10 , wherein R 12 is pyrimidin-5-yl or pyridin-3-yl.
12. The method of claim 10 , wherein R 12 is substituted with alkyl or alkoxy.
13. The method of claim 12 , wherein R 12 is 2-methoxy-pyrimidin-5-yl, 3-methoxyphenyl, 2-methoxy-pyridin-3-yl, 2-methyl-pyrimidin-5-yl, or tetrahydropyran-4-yl.
14. The method of claim 13 , wherein R 1 is H.
15. The method of claim 1 , wherein the compound has one of the following structures or is a pharmaceutically acceptable salt thereof:
16. The method of claim 15 , wherein the compound has the following structure or is a pharmaceutically acceptable salt thereof:
17. The method of claim 16 , wherein the genus of the protozoan is Toxoplasma.
18. The method of claim 17 , wherein the infection is toxoplasmosis.